ST Huicheng Restructuring Plan Draft Approved, Focusing on Pharmaceutical Industry

Corporate Action
โดย CLS·Read original
Summary · why it matters

ST Huicheng announced that the operating plan for the pre-restructuring reorganization agreement and restructuring plan draft has been finalized. The company will retain its pharmaceutical segment assets and focus on the development of the pharmaceutical industry. The restructuring investor is Zhien Biotechnology, with designated financial investors including Shanyuan Runhe, Chongqing Lizhu, and CICC Pucheng. The total consideration for the restructuring investors' subscription of converted shares is 790 million yuan, to be used for bankruptcy expenses, debt repayment, and subsequent operations. Non-retained assets will be disposed of through the establishment of an enterprise bankruptcy service trust, with the underlying assets having a market value of 616 million yuan and a liquidation value of 258 million yuan. Regarding employee placement, salaries will remain unchanged after the restructuring, and re-employment training will be provided.

Impact on stocks 1

Others▲ · 1 stocks

Off-coverage companies 4

植恩生物技术股份有限公司Private▲ Positive
Capitalrelevance

Zhien Biotechnology is the restructuring investor, acquiring converted shares

Zhongjin Pucheng Investment Co., Ltd. (中金浦成投资有限公司)Private▲ Positive
Capitalrelevance

CICC Pucheng is a designated financial investor in the restructuring

重庆山源润合私募股权投资基金合伙企业（有限合伙）Private▲ Positive
Capitalrelevance

Shanyuan Runhe is a designated financial investor in the restructuring

重庆骊珠Private▲ Positive
Capitalrelevance

Chongqing Lizhu is a designated financial investor in the restructuring

© 2026 MarketDXNews